Nature Reviews Cancer

Nature Reviews Cancer
Title	Nature Reviews Cancer
Discipline	Oncology
Abbreviation	Nat. Rev. Cancer
Publisher	Nature Portfolio
Country	United Kingdom
Frequency	Monthly
History	2001–present

Nature Reviews Cancer Nature Reviews Cancer is a monthly peer-reviewed review journal published by Nature Portfolio that synthesizes advances in oncology, molecular biology, and clinical trial research for a global audience of clinicians, researchers, and policy-makers. It integrates commentary on basic science developments from laboratories such as Cold Spring Harbor Laboratory and The Francis Crick Institute with translational perspectives relevant to institutions like Memorial Sloan Kettering Cancer Center and Mayo Clinic. The journal situates discoveries from groups associated with awards like the Nobel Prize in Physiology or Medicine alongside work produced at universities such as Harvard University, Stanford University, and University of Cambridge.

Overview

Nature Reviews Cancer provides in-depth review articles, perspectives, commissioned essays, and expert commentaries that link discoveries in cell biology at centers like Max Planck Society with clinical applications trialed at Dana-Farber Cancer Institute and MD Anderson Cancer Center. Each issue curates content on topics ranging from targeted therapies developed following findings at Broad Institute to immuno-oncology strategies emerging from collaborations with Karolinska Institutet and Johns Hopkins University. The journal frequently spotlights work by investigators connected to prizes such as the Lasker Award and to consortia including The Cancer Genome Atlas and International Agency for Research on Cancer.

History and development

Launched in 2001 by the publishing group now known as Nature Portfolio, the journal evolved during the post-genomic era shaped by initiatives like Human Genome Project and biobank efforts at UK Biobank. Early editorial direction responded to paradigm shifts driven by discoveries from laboratories at European Molecular Biology Laboratory and translational hubs such as Sloan Kettering Institute. Over successive editorial tenures, the publication reflected changing priorities from targeted small-molecule development referenced in patents from Pfizer and Novartis to immune-based approaches linked to corporate collaborations with Roche and Merck & Co.. Its development paralleled policy debates involving organizations like World Health Organization and funding patterns from agencies such as National Institutes of Health and Cancer Research UK.

Editorial scope and content

The journal commissions comprehensive reviews from established investigators at institutions like University of California, San Francisco and Yale University, covering mechanisms identified in studies at National Cancer Institute and therapeutic advances from trials run by cooperative groups such as EORTC and SWOG. Regular sections include thematic reviews synthesizing results from landmark studies published in venues such as The Lancet Oncology and Journal of Clinical Oncology, opinion pieces reflecting viewpoints of editorial boards connected to Royal Society fellows, and timelines that contextualize breakthroughs akin to those recognized by the National Medal of Science. Content spans molecular pathways elucidated at Cold Spring Harbor Laboratory, biomarker discovery reported by teams at Wellcome Sanger Institute, and health-systems implications examined alongside organizations like American Society of Clinical Oncology.

Impact and reception

Nature Reviews Cancer is widely cited in academic literature and referenced in guidelines produced by professional bodies such as NCCN and European Society for Medical Oncology. Its articles influence translational research agendas at centers including Fred Hutchinson Cancer Research Center and inform regulatory discussions involving agencies like European Medicines Agency and U.S. Food and Drug Administration. Critical reception in scholarly forums and at meetings like American Association for Cancer Research highlights the journal’s role in framing debates about controversies exemplified by high-profile cases from institutions such as Mayo Clinic and by landmark trials conducted at Memorial Sloan Kettering Cancer Center.

Abstracting and indexing

The journal is indexed in major databases and services that track biomedical literature produced by organizations like Clarivate and Elsevier. It appears in citation indexes used by universities including Oxford University and University of Toronto for assessment, and is discoverable through library systems at institutions such as Columbia University and Imperial College London. Abstracting coverage aligns with platforms relied on by researchers at Massachusetts Institute of Technology and by clinicians at Cleveland Clinic.

Notable publications and special issues

Notable reviews and special issues have synthesized progress in areas tied to initiatives like The Cancer Genome Atlas and technology developments from firms such as Illumina; topics have included precision oncology reviews that reference landmark studies from Memorial Sloan Kettering Cancer Center, immunotherapy retrospectives connected to work at Parker Institute for Cancer Immunotherapy and translational summaries influenced by discoveries at Salk Institute for Biological Studies. Special themed collections have coincided with conferences such as ASCO Annual Meeting and have featured contributions from Nobel laureates affiliated with Rockefeller University and MIT. These collections often serve as touchstones cited by policymakers at World Health Organization and funding bodies like Wellcome Trust.

Category:Medical journals